Type 2 diabetes mellitus (T2DM) is characterized by a progressive decline in beta-cell function with insulin resistance[@b1][@b2][@b3]. Beta-cell dysfunction and insulin resistance are the central mechanisms in the pathogenesis of T2DM. As a surrogate marker for measuring beta-cell function and insulin sensitivity, the homoeostasis model assessment (HOMA) indexes, which are based on fasting glucose and insulin levels, have been widely used for decades in clinical and epidemiological research[@b4][@b5]. The validity of HOMA indexes have been confirmed against the hyperglycemic and euglycemic clamps and the intravenous glucose tolerance test[@b4]. Recently, the Whitehall II study has shown that beta-cell function and insulin sensitivity as measured by HOMA beta-cell function (HOMA-B) and HOMA insulin resistance (HOMA-IR) may undergo significant reduction several years before the diagnosis of T2DM[@b6]. The UK Prospective Diabetes Study (UKPDS) has demonstrated that HOMA-B continues to deteriorate in association with progressively increasing hyperglycemia despite treatment[@b7]. These data highlight the importance of preserving beta-cell function and insulin sensitivity in the prevention and management of T2DM.

Dipeptidyl peptidase-4 (DPP-4) inhibitors are a novel family of glucose-lowering agents that are increasingly used in clinical practice in treating T2DM patients. DPP-4 is responsible for the degradation of incretin hormones such as glucagon-like peptide 1 (GLP-1)[@b8]. Inhibition of DPP-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in T2DM patients[@b9]. DPP-4 inhibitors have many favorable features including a low risk of hypoglycemia and a neutral effect on body weight[@b8]. In addition, they are efficacious and well tolerated as mono-therapy and also as add-on therapy in combination with commonly prescribed anti-diabetic agents and are suitable for once-daily oral dosing[@b8][@b10]. As a result, the American Diabetes Association and the European Association for the Study of Diabetes recommend DPP-4 inhibitors as part of a combination therapy with metformin and/or other agents or as a preferable monotherapy choice for patients in whom metformin is contraindicated or not tolerated[@b11][@b12].

The underlying mechanisms of DPP-4 inhibitors in the management of T2DM remain to be understood, and the roles of DPP-4 inhibitors on beta-cell function and insulin sensitivity are of particular interest. Experimental data show that DPP-4 inhibitors may help preserve pancreatic beta-cell function[@b13][@b14]. However, results from previous studies in humans have been inconsistent, partly because of the limited sample size and insufficient statistical power in some individual studies. In this study, we aimed to systematically review the available evidence and quantitatively summarize the findings by performing a meta-analysis of randomized controlled trials (RCTs).

Material and Methods
====================

This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement[@b15].

Study selection
---------------

Articles were eligible for inclusion if they fulfilled all the following criteria: (i) they were RCTs; (ii) the participants were patients with T2DM; (iii) they compared a DPP-4 inhibitor as monotherapy or add-on therapy with an appropriate control; (iv) they provided information on HOMA-estimated beta-cell function or insulin resistance; (v) the study duration was no less than 12 weeks; and (vi) the results were published in peer-reviewed journal as a full paper. We excluded the following types of articles: review articles or editorials, non-human studies (i.e., cell culture or animal studies), studies that did not include DPP-4 inhibitor treatment in the intervention group, and studies that did not evaluate beta-cell function or insulin resistance. Disagreement about eligibility was resolved by consensus between all authors.

Literature search
-----------------

We performed a comprehensive literature search in the PubMed, EMBASE, and Cochrane Library databases. The last search update was conducted on up to December 27, 2016. In terms of the database search strategy, we used a combination of free text (e.g., type 2 diabetes) and subheadings from MeSH (e.g., "Diabetes Mellitus, Type 2" \[Mesh\]) or EMTREE terms (e.g., 'non insulin dependent diabetes mellitus'/exp). In addition to using the generic term for DPP-4 inhibitors, we also specifically named each major DPP-4 inhibitor (e.g., Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Anagliptin, Teneligliptin, Alogliptin, Gemigliptin, and Dutogliptin) when conducting the literature search. More detailed search terms are listed in the [Supplementary Materials](#S1){ref-type="supplementary-material"}. The reference lists of relevant studies and review articles were also checked to identify additional relevant studies.

Data extraction
---------------

The following data were extracted from each eligible article: the first author's name, year of publication, sample size, participants' age, T2DM duration, types of DPP-4 inhibitors tested, study duration, mean baseline HbA1c, and mean and standard deviation of HOMA indexes in the comparison groups. When necessary, we contacted the corresponding authors of the original articles by email to request relevant data or information. If multiple articles were published using data from the same study, we extracted the report with the information most relevant to the analysis. If the same trial reported data at different follow-up durations[@b16][@b17][@b18], we extracted the data corresponding to the longest follow-up period[@b18]. If a study reported results on the effects of DPP-4 inhibitors at different doses, we extracted data corresponding to the standard dosages for each DPP-4 inhibitor (e.g., sitagliptin 100 mg/day; saxagliptin 5 mg/day; vildagliptin 100 mg/day; linagliptin 5 mg/day; teneligliptin 20 mg/day; and alogliptin 25 mg/day) unless otherwise specified.

Quality assessment of the included RCTs
---------------------------------------

Assessment of risk of bias in the included RCTs was performed according to the Cochrane Collaboration's tool[@b19], which includes the following domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. The risk of bias in each domain was assessed as low, high, or unclear.

Data synthesis and statistical analysis
---------------------------------------

We calculated weighted mean differences (WMDs) and 95% confidence intervals (CIs) for the change in HOMA indexes from baseline to the end of the trial for DPP-4 inhibitors versus controls reported in each of the included trials and pooled the data in the meta-analysis using a random-effects model[@b20]. If both adjusted (typically derived from analysis of covariance) and unadjusted changes from baseline were reported in a trial, we selected the adjusted estimates as they accounted for possible baseline imbalance and the correlation between baseline and follow-up measures. When the adjusted estimates were not available, we limited meta-analyses to those trials with baseline balance in HOMA indexes[@b21]. When standard deviations of the change from baseline were not reported in the article, we converted standard errors or 95% CIs to standard deviations.

We used forest plots to visualize the effect sizes in each individual study and the pooled overall effect size. We assessed between-study heterogeneity using the χ^2^-based Cochrane's Q statistic and the *I*^2^ metric (*I*^2^ values of 25%, 50%, and 75% were considered to indicate low, medium, and high heterogeneity, respectively)[@b22]. Potential of publication bias is assessed by funnel plots, in which asymmetrical plot indicates presence of reporting bias. To explore the possible differences in the effectiveness of individual DPP-4 inhibitors on beta-cell function and insulin sensitivity, we performed stratification analysis according to the type of DPP-4 inhibitor tested. Sensitivity analyses were performed by omitting one study at a time and computing the pooled effect size of the remaining studies to evaluate whether the results were affected markedly by a single study. All statistical analyses were performed using Stata software version 11.0 (Stata Corp, College Station, TX, USA).

Results
=======

Characteristics of the included studies
---------------------------------------

We identified 589 potentially relevant articles from database search and other resources. After screening, 278 articles were evaluated in detail and 52 articles presenting RCTs[@b16][@b18][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b41][@b42][@b43][@b44][@b45][@b46][@b47][@b48][@b49][@b50][@b51][@b52][@b53][@b54][@b55][@b56][@b57][@b58][@b59][@b60][@b61][@b62][@b63][@b64][@b65][@b66][@b67][@b68][@b69][@b70][@b71][@b72] were finally included in the meta-analysis ([Fig. 1](#f1){ref-type="fig"}). Of them, 23 articles reported data from trials using DPP-4 inhibitors as monotherapy, 28 articles from trials using DPP-4 inhibitors as adds-on therapy, and the other one article involving mixed study design using DPP-4 inhibitors as both monotherapy and adds-on therapy.

The baseline characteristics of the included RCTs in the meta-analysis are shown in [Table 1](#t1){ref-type="table"}. The majority of studies were conducted in Caucasian or Asian populations. Sitagliptin was the most investigated drug among DPP-4 inhibitors as monotherapy and add-on therapy in the included studies. Most of the included RCTs had a relatively short study duration (typically 12 or 24 weeks). The risk of bias varied across the individual trials. All the included trials, except one[@b56], involved appropriate double blind procedures, and none were associated with concerns about selective outcome reporting. However, in some of the included trials, HOMA-IR or HOMA-B data were missing for more than 20% of the participants, because these indicators were not the primary outcome and therefore were not assessed all participants. In addition, information regarding random generation sequence, allocation concealment, and blinding of outcome assessment was not clearly described in most trials ([Supplementary Table 1](#S1){ref-type="supplementary-material"}).

Effects of DPP-4 inhibitors as monotherapy on beta-cell function and insulin resistance
---------------------------------------------------------------------------------------

Our meta-analysis of 23 RCTs showed that DPP-4 inhibitors as monotherapy significantly improved beta-cell function ([Fig. 2](#f2){ref-type="fig"}). The pooled WMD (95% CI) for the HOMA-B was 9.15 (7.48, 10.81). We observed no evidence for significant heterogeneity (*I*^2^ = 4%, *P* = 0.41). For insulin resistance, we found no significant improvement after treatment with DPP-4 inhibitors as monotherapy ([Fig. 3](#f3){ref-type="fig"}). Sensitivity analyses conducted by omitting one study at a time did not show significant alteration of the results.

Effects of DPP-4 inhibitors as add-on therapy on beta-cell function and insulin resistance
------------------------------------------------------------------------------------------

In a meta-analysis of 28 RCTs, we found that treatment with DPP-4 inhibitors as add-on therapy in combination with other drugs significantly improved beta-cell function ([Fig. 4](#f4){ref-type="fig"}). The pooled WMD (95% CI) for the HOMA-B was 9.04 (5.72, 12.37). There was evidence for significant heterogeneity (*I*^2^ = 89%, *P* \< 0.001). Similar to the findings for DPP-4 inhibitor monotherapy, we found no significant improvement in insulin resistance after treatment with DPP-4 inhibitors as monotherapy ([Fig. 5](#f5){ref-type="fig"}). Sensitivity analyses conducted by omitting one study at a time did not show significant alteration of the results.

Publication bias
----------------

In the funnel plots, we observed evidence of publication bias (i.e., asymmetrical plots) in the meta-analysis of DPP-4 inhibitors as either monotherapy ([Supplementary Figures 1 and 2](#S1){ref-type="supplementary-material"}) or add-on therapy ([Supplementary Figures 3 and 4](#S1){ref-type="supplementary-material"}) on beta-cell function and insulin resistance. However, these results should be interpreted with caution, because asymmetrical plots may also be a result of other reasons, such as small study effects, rather than publication bias.

Comparative effects of individual DPP-4 inhibitors as monotherapy
-----------------------------------------------------------------

In stratification analyses according to the types of DPP-4 inhibitors, we pooled data for each DPP-4 inhibitor. We found that treatment with all types of DDP-4 inhibitors except for linagliptin resulted in an increase in HOMA-B ([Supplementary Figure 5](#S1){ref-type="supplementary-material"}). In the meta-analysis of the effects of individual DPP-4 inhibitors on insulin resistance ([Supplementary Figure 6](#S1){ref-type="supplementary-material"}), we observed a significant improvement in insulin resistance with sitagliptin treatment without evidence of significant heterogeneity (WMD −0.38; 95% CI −0.69, −0.08; *I*^2^ = 0%, *P* for heterogeneity = 0.58). Linagliptin seemed to have a trend to increase insulin resistance, but the results should be interpreted cautiously due to the limited number of available studies. We found no significant effects of other DPP-4 inhibitors on insulin resistance.

Discussion
==========

Our meta-analysis of data from 52 RCTs showed that DPP-4 inhibitors as monotherapy or as add-on therapy significantly improved beta-cell function as measured by the HOMA-B. However, there was no significant improvement in insulin resistance with the use of DPP-4 inhibitors as monotherapy or as add-on therapy in combination with other drugs. Consistent with the results of previous meta-analyses[@b73][@b74], these findings provide important insight into the pathophysiological mechanisms of DPP-4 inhibitor action in the treatment of T2DM.

Our results regarding the effects of DPP-4 inhibitor treatment on beta-cell function were largely consistent with results from the largest trials using DPP-4 inhibitors as monotherapy[@b75], adds-on therapy[@b66], or mixed trial design involving multiple trials[@b62]. In the trial by Pratley *et al*.[@b75], vildagliptin monotherapy yielded consistently robust improvement in beta-cell function, measured not only by HOMA-B based on fasting glucose and insulin but also by meal test-derived measures, across a broad spectrum of drug-naive patients with T2DM. In addition, our findings were consistent with those of other studies that measured dynamic beta-cell function after meal ingestion. For instance, in a meal tolerance test performed with a double tracer technique (3-(3)H-glucose iv and 1-(14)C-glucose orally), the DPP-4 inhibitor vildagliptin significantly increased the insulin secretion rate divided by plasma glucose by 29% in T2DM patients[@b76]. When added to metformin therapy in patients with T2DM, vildagliptin treatment resulted in a significant increase in insulin secretion (postmeal suprabasal area under the 0- to 30-min C-peptide curve divided by the 30-min increase in glucose)[@b77].

The favorable effects of DPP-4 inhibitors for improving beta-cell function among patients with T2DM are biologically plausible[@b78]. DPP-4 inhibitor treatment in diabetic animal models stimulated beta-cell survival, facilitated islet neogenesis, enhanced insulin biosynthesis[@b79], and preserved beta-cell mass and function[@b13]. Moreover, DPP-4 gene knockout mice showed better insulin sensitivity and less pancreatic islet hypertrophy and were resistant to streptozotocin-induced loss of beta-cell mass and hyperglycemia[@b80]. In humans with T2DM, DPP-4 inhibitors have demonstrated improvement of beta-cell function both in the fasting and postprandial statuses, and these beneficial effects were sustained in studies with a duration up to 2 years[@b78]. DPP-4 inhibitors may restore beta-cell function and survival in isolated human islets through glucagon-like peptide (GLP)-1 stabilization[@b81]. In addition, DPP-4 inhibitors also exert an anti-inflammatory effect[@b82][@b83], which may alleviate the loss of beta-cell function[@b84]. Recently, it is reported that DPP-4 inhibitors may protect pancreatic beta-cells by elongating the telomere length[@b85]. However, there is a lack of evidence in humans to demonstrate the durable effects of DPP-4 inhibitors on beta-cell function after cessation of therapy in patients with T2DM, which warrants further investigation in long-term, well-designed trials with a sufficiently long washout period after discontinuation of the study drug[@b78].

In general, DPP-4 inhibitors showed no effects on insulin resistance. While the underlying mechanisms remain to be elucidated, this finding may be at least partly due to the neutral effects of DPP-4 inhibitors on body weight[@b8]. Interestingly, our meta-analysis showed that sitagliptin, but not the other tested DPP-4 inhibitors, as monotherapy resulted in significant improvement in insulin resistance. This finding needs to be confirmed in future studies.

The study has strengths in that it was conducted using a systematic approach and the results are based on a large number of published RCTs. However, there are several limitations. First, most of the included studies had a follow-up duration of less than 6 months. The longer-term effects of DPP-4 inhibitor treatment on beta-cell function and insulin resistance in patients with T2DM warrant further investigation. Second, our study had a lack of power to compare the effectiveness of DPP-4 inhibitors in this study, because the number of available trials for some individual DPP-4 inhibitors was still limited. DPP-4 inhibitors have similar but still varying pharmacological features[@b86][@b87], and thus, their effects on beta-cell function and insulin resistance may vary. Third, we used the HOMA-B as the indicator of beta-cell function. Because this parameter is originally estimated based on fasting glucose and insulin levels, it may not sufficiently represent postprandial beta-cell function. Fourth, publication bias may exist regarding the effects of DPP-4 inhibitors on beta-cell function.

In conclusion, among patients with T2DM, DPP-4 inhibitors as monotherapy or as add-on therapy in combination with other drugs significantly improved beta-cell function but had no significant effect on insulin resistance.
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###### Characteristics of the RCTs included in the meta-analysis.

  Author, year                      Study design                      Intervention                                        Control                     No. of subjects (Int/Ctrl)   Mean age (years)   Mean BMI (kg/m^2^)   Mean T2DM duration (years)   Mean baseline HbA1c   Study duration (weeks)
  -------------------------------- -------------- ----------------------------------------------------- -------------------------------------------- ---------------------------- ------------------ -------------------- ---------------------------- --------------------- ------------------------
  Ristic *et al*.[@b23]             Monotherapy                    Vildagliptin 100 mg                                    Placebo                               53/58                    55.0                31.4                     2.7                       7.7                     12
  Aschner *et al*.[@b24]            Monotherapy                    Sitagliptin 100 mg                                     Placebo                              238/253                   54.0                30.5                     4.5                       8.0                     24
  Charbonnel *et al*.[@b25]           Add-ons                Sitagliptin 100 mg + Metformin                         Placebo + Metformin                        464/237                   54.5                31.0                     6.3                       8.0                     24
  Pratley *et al*.[@b26]            Monotherapy                    Vildagliptin 50 mg                                     Placebo                               70/28                    54.0                30.0                     4.0                       8.1                     12
  Raz *et al*.[@b27]                Monotherapy                    Sitagliptin 100 mg                                     Placebo                              205/110                   55.5                32.0                     4.6                       8.0                     18
  Rosenstock *et al*.[@b28]           Add-ons               Sitagliptin 100 mg + Pioglitazone                      Placebo + Pioglitazone                      175/178                   56.0                31.5                     6.1                       8.0                     24
  Goldstein *et al*.[@b16]          Monotherapy                    Sitagliptin 100 mg                                     Placebo                              179/176                   53.4                32.0                     4.5                       8.8                     24
  Hanefeld *et al*.[@b29]           Monotherapy                    Sitagliptin 100 mg                                     Placebo                              110/111                   56.0                31.5                     3.5                       7.7                     12
  Hermansen *et al*.[@b30]            Add-ons         Sitagliptin 100 mg + Glimepiride ± Metformin           Placebo + Glimepiride ± Metformin                 222/219                   55.0                31.0                     8.8                       8.3                     24
  Scott *et al*.[@b31]              Monotherapy                    Sitagliptin 100 mg                                     Placebo                              124/125                   55.2                31.0                     4.5                       9.5                     12
  DeFronzo *et al*.[@b32]           Monotherapy                     Alogliptin 25 mg                                      Placebo                               131/64                   53.4                 NR                       NR                       7.9                     26
  Nonaka *et al*.[@b33]             Monotherapy                    Sitagliptin 100 mg                                     Placebo                               75/76                    55.3                25.0                     4.0                       7.6                     12
  Pratley *et al*.[@b34]            Monotherapy                    Vildagliptin 100 mg                                    Placebo                              1470/182                  53.0                32.3                     2.2                       8.5                     24
  Raz *et al*.[@b35]                  Add-ons                Sitagliptin 100 mg + Metformin                              Metformin                              96/94                    54.0                30.3                     7.8                       9.2                     18
  Rosenstock *et al*.[@b36]         Monotherapy                     Saxagliptin 5 mg                                      Placebo                               106/95                   54.0                31.0                     2.4                       8.0                     12
  Scott *et al*.[@b37]                Add-ons                Sitagliptin 100 mg + Metformin                              Metformin                              94/92                    55.3                30.0                     5.2                       7.8                     18
  Chacra *et al*.[@b38]               Add-ons                 Saxagliptin 5 mg + Glyburide                          Placebo + Glyburide                        253/267                   55.0                29.0                     6.8                       8.4                     24
  DeFronzo *et al*.[@b39]             Add-ons                 Saxagliptin 5 mg + Metformin                               Metformin                             191/179                   54.8                31.4                     6.5                       8.1                     24
  Hollander *et al*.[@b40]            Add-ons             Saxagliptin 5 mg + Thiazolidinediones                      Thiazolidinediones                        186/184                   53.6                30.0                     5.2                       8.3                     24
  Mohan *et al*.[@b41]              Monotherapy                    Sitagliptin 100 mg                                     Placebo                              352/178                   50.0                25.0                     2.0                       8.8                     18
  Rosenstock *et al*.[@b42]         Monotherapy                     Saxagliptin 5 mg                                      Placebo                               106/95                   54.0                31.0                     2.4                       8.0                     24
  Forst *et al*.[@b43]                Add-ons                 Linagliptin 5 mg + Metformin                               Metformin                              66/71                    60.0                32.0                     6.8                       8.5                     12
  Rhee *et al*.[@b44]               Monotherapy                     Gemigliptin 50 mg                                     Placebo                               35/34                    52.0                25.3                     4.4                       8.2                     12
  Williams-Herman *et al*.[@b18]      Add-ons                Sitagliptin 100 mg + Metformin                              Metformin                              107/88                   54.0                31.5                     4.2                       8.7                    104
  Bosi *et al*.[@b45]                 Add-ons          Alogliptin 25 mg + Metformin + Pioglitazone                Metformin + Pioglitazone                     404/399                   55.0                31.5                     7.0                       8.1                     52
  Del Prato *et al*.[@b46]          Monotherapy                     Linagliptin 5 mg                                      Placebo                              336/167                   55.0                29.1                      NR                       8.0                     24
  Gomis *et al*.[@b47]                Add-ons                Linagliptin 5 mg + Pioglitazone                            Pioglitazone                           259/130                   57.4                29.0                      NR                       8.6                     24
  Kaku *et al*.[@b48]                 Add-ons                Alogliptin 25 mg + Pioglitazone                       Placebo + Pioglitazone                      113/115                   60.0                26.3                     6.8                       7.9                     12
  Owens *et al*.[@b49]                Add-ons         Linagliptin 5 mg + Metformin + Sulphonylurea          Placebo + Metformin + Sulphonylurea                541/175                   58.0                28.0                      NR                       8.1                     24
  Reasner *et al*.[@b50]              Add-ons                Sitagliptin 100 mg + Metformin                              Metformin                             625/621                   50.0                33.0                     3.4                       9.9                     18
  Seino *et al*.[@b51]                Add-ons                 Alogliptin 25 mg + Voglibose                               Voglibose                              79/75                    62.5                24.0                     8.0                       8.0                     12
  Seino *et al*.[@b52]              Monotherapy                     Alogliptin 25 mg                                      Placebo                               80/75                    59.3                24.5                     6.9                       7.9                     12
  Taskinen *et al*.[@b53]             Add-ons                 Linagliptin 5 mg + Metformin                               Metformin                             523/177                   56.6                30.0                      NR                       8.1                     24
  Yoon *et al*.[@b54]                 Add-ons               Sitagliptin 100 mg + Pioglitazone                           Pioglitazone                           261/259                   51.0                29.7                     2.4                       9.5                     24
  Kawamori *et al*.[@b55]           Monotherapy                     Linagliptin 5 mg                                      Placebo                               159/80                   60.0                24.5                      NR                       8.0                     12
  Kutoh *et al*.[@b56]              Monotherapy                     Alogliptin 25 mg                                        Diet                                25/26                    48.0                26.3                      0                       10.3                     12
  Pan *et al*.[@b57]                Monotherapy                     Saxagliptin 5 mg                                      Placebo                              284/284                   51.4                25.9                     1.0                       8.1                     24
  Seino *et al*.[@b58]                Add-ons                 Alogliptin 25 mg + Metformin                               Metformin                              96/100                   52.2                25.0                     6.3                       8.0                     12
  Dobs *et al*.[@b59]                 Add-ons        Sitagliptin 100 mg + Metformin + rosiglitazone              Metformin + rosiglitazone                      170/92                   54.6                30.5                     9.3                       8.8                     54
  Kadowaki *et al*.[@b60]           Monotherapy                    Teneligliptin 20 mg                                    Placebo                               79/80                    58.8                25.1                     6.0                       7.9                     12
  Zeng *et al*.[@b61]                 Add-ons         Linagliptin 5 mg + Metformin + Sulphonylurea          Placebo + Metformin + Sulphonylurea                 144/48                   56.0                25.8                      NR                       8.1                     12
  Heise *et al*.[@b62]                 Mixed       Linagliptin 5 mg + Various antidiabetic medications   Placebo + Various antidiabetic medications            1905/796                  57.0                29.3                      NR                       8.2                     24
  Yokoyama *et al*.[@b63]             Add-ons              Sitagliptin 100 mg + Sulfonylureas                   Liraglutide + Sulfonylureas                     49/50                    61.3                25.9                     11.3                      7.8                     24
  Fukui *et al*.[@b64]              Monotherapy                     Sitagliptin 50 mg                                  Sulfonylureas                            21/22                    66.3                26.3                     7.5                       7.3                     24
  Jung *et al*.[@b65]               Monotherapy                 Evogliptin (DA1229) 5 mg                                  Placebo                               43/48                    54.3                25.5                     3.7                       7.6                     12
  Leibowitz *et al*.[@b66]            Add-ons      Saxagliptin 5 mg + Various antidiabetic medications   Placebo + Various antidiabetic medications           2408/2312                  65.2                31.1                     8.3                       7.5                    151
  Strozik *et al*.[@b67]              Add-ons                Vildagliptin 100 mg + Metformin                             Metformin                              17/16                    55.0                32.0                      NR                       8.1                     12
  Yokoh *et al*.[@b68]              Monotherapy                     Sitagliptin 50 mg                           Alpha-glucosidase inhibitor                     58/58                    58.5                26.1                     6.8                       7.6                     24
  Zografou *et al*.[@b69]             Add-ons                Vildagliptin 50 mg + Metformin                              Metformin                              32/32                    54.4                31.9                      NR                       8.1                     24
  Ba *et al*.[@b70]                   Add-ons        Sitagliptin 100 mg + Sulfonylureas ± Metformin         Placebo + Sulfonylureas ± Metformin                249/249                   56.0                25.4                     7.0                       8.5                     24
  Ekholm *et al*.[@b71]               Add-ons         Saxagliptin 5 mg + Dapagliflozin + Metformin          Placebo + Dapagliflozin + Metformin                160/152                   54.0                 32                      7.3                       8.9                     24
  Oyama *et al*.[@b72]                Add-ons         Sitagliptin 25--100 mg + Conventional therapy                 Conventional therapy                       222/220                   69.3                25.1                      NR                       7.0                     24

Abbreviations: Int, intervention group; Ctrl, control group; BMI, body mass index; T2DM, type 2 diabetes mellitus; HbA1c, hemoglobin A1c; NR, not reported.
